A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19

NCT03891420 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to no longer pursue indications studied in this trial

Conditions

COVID-19
Yellow Fever

Interventions

DRUG: Galidesivir
DRUG: Placebo

Sponsor

BioCryst Pharmaceuticals

Collaborators

[object Object]